Browse CEBPD

Summary
SymbolCEBPD
NameCCAAT/enhancer binding protein (C/EBP), delta
Aliases CELF; C/EBP-delta; NF-IL6-beta; c/EBP delta; nuclear factor NF-IL6-beta; CCAAT/enhancer-binding protein delt ......
Chromosomal Location8p11.2-p11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus
Domain PF07716 Basic region leucine zipper
Function

Transcription activator that recognizes two different DNA motifs: the CCAAT homology common to many promoters and the enhanced core homology common to many enhancers (PubMed:16397300). Important transcription factor regulating the expression of genes involved in immune and inflammatory responses (PubMed:1741402, PubMed:16397300). Transcriptional activator that enhances IL6 transcription alone and as heterodimer with CEBPB (PubMed:1741402).

> Gene Ontology
 
Biological Process GO:0001503 ossification
GO:0001649 osteoblast differentiation
GO:0002244 hematopoietic progenitor cell differentiation
GO:0007423 sensory organ development
GO:0030278 regulation of ossification
GO:0043583 ear development
GO:0045444 fat cell differentiation
GO:0045667 regulation of osteoblast differentiation
GO:0045669 positive regulation of osteoblast differentiation
GO:0045778 positive regulation of ossification
GO:0048839 inner ear development
Molecular Function GO:0000978 RNA polymerase II core promoter proximal region sequence-specific DNA binding
GO:0000982 transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0000987 core promoter proximal region sequence-specific DNA binding
GO:0001077 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0001159 core promoter proximal region DNA binding
GO:0001228 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding
GO:0046982 protein heterodimerization activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-1266738: Developmental Biology
R-HSA-168256: Immune System
R-HSA-6785807: Interleukin-4 and 13 signaling
R-HSA-449147: Signaling by Interleukins
R-HSA-381340: Transcriptional regulation of white adipocyte differentiation
Summary
SymbolCEBPD
NameCCAAT/enhancer binding protein (C/EBP), delta
Aliases CELF; C/EBP-delta; NF-IL6-beta; c/EBP delta; nuclear factor NF-IL6-beta; CCAAT/enhancer-binding protein delt ......
Chromosomal Location8p11.2-p11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CEBPD and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between CEBPD and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
23861541Nasopharyngeal CarcinomaInhibit immunityWe showed that immunosuppressive prostaglandin E? (PGE?) led to the production and activity of the transcription factor CCAAT/enhancer binding protein δ (C/EBPδ) by stimulating the nucleocytoplasmic shuttling of the RNA binding protein Hu antigen R (HuR), which bound to and stabilized CEBPD mRNA in macrophages. An increase in C/EBPδ abundance in macrophages in response to PGE? resulted in enhanced production of the immunosuppressive cytokine interleukin-10 (IL-10) and of pentraxin 3 (PTX3), which suppresses the ability of macrophages to phagocytose tumor cells.
Summary
SymbolCEBPD
NameCCAAT/enhancer binding protein (C/EBP), delta
Aliases CELF; C/EBP-delta; NF-IL6-beta; c/EBP delta; nuclear factor NF-IL6-beta; CCAAT/enhancer-binding protein delt ......
Chromosomal Location8p11.2-p11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CEBPD in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCEBPD
NameCCAAT/enhancer binding protein (C/EBP), delta
Aliases CELF; C/EBP-delta; NF-IL6-beta; c/EBP delta; nuclear factor NF-IL6-beta; CCAAT/enhancer-binding protein delt ......
Chromosomal Location8p11.2-p11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CEBPD in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.3630.481
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.0810.67
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.1530.939
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.0880.88
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.4260.86
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.340.913
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.3030.457
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.2590.81
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.4410.732
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.3540.766
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.0390.983
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.4180.0011
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CEBPD in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCEBPD
NameCCAAT/enhancer binding protein (C/EBP), delta
Aliases CELF; C/EBP-delta; NF-IL6-beta; c/EBP delta; nuclear factor NF-IL6-beta; CCAAT/enhancer-binding protein delt ......
Chromosomal Location8p11.2-p11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CEBPD. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCEBPD
NameCCAAT/enhancer binding protein (C/EBP), delta
Aliases CELF; C/EBP-delta; NF-IL6-beta; c/EBP delta; nuclear factor NF-IL6-beta; CCAAT/enhancer-binding protein delt ......
Chromosomal Location8p11.2-p11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CEBPD. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CEBPD.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCEBPD
NameCCAAT/enhancer binding protein (C/EBP), delta
Aliases CELF; C/EBP-delta; NF-IL6-beta; c/EBP delta; nuclear factor NF-IL6-beta; CCAAT/enhancer-binding protein delt ......
Chromosomal Location8p11.2-p11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CEBPD. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCEBPD
NameCCAAT/enhancer binding protein (C/EBP), delta
Aliases CELF; C/EBP-delta; NF-IL6-beta; c/EBP delta; nuclear factor NF-IL6-beta; CCAAT/enhancer-binding protein delt ......
Chromosomal Location8p11.2-p11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CEBPD expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCEBPD
NameCCAAT/enhancer binding protein (C/EBP), delta
Aliases CELF; C/EBP-delta; NF-IL6-beta; c/EBP delta; nuclear factor NF-IL6-beta; CCAAT/enhancer-binding protein delt ......
Chromosomal Location8p11.2-p11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CEBPD and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCEBPD
NameCCAAT/enhancer binding protein (C/EBP), delta
Aliases CELF; C/EBP-delta; NF-IL6-beta; c/EBP delta; nuclear factor NF-IL6-beta; CCAAT/enhancer-binding protein delt ......
Chromosomal Location8p11.2-p11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CEBPD collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.